Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213652 | 0.92 | PPARG (0.33) | FFAR1PPARGPPARAESR1 | |
| SCHEMBL14299360 | 0.82 | PPARG (0.35) | FFAR1PPARG | |
| SCHEMBL14299381 | 0.82 | PPARG (0.46) | FFAR1PPARG | |
| SCHEMBL14299382 | 0.82 | PPARG (0.37) | FFAR1PPARG | |
| SCHEMBL14213661 | 0.82 | PPARG (0.36) | FFAR1PPARGPPARA | |
| SCHEMBL14213690 | 0.79 | FFAR1 (0.33) | FFAR1PPARGESR1 | |
| SCHEMBL6928374 | 0.78 | PPARG (0.48) | FFAR1PPARGPPARA | |
| SCHEMBL14213639 | 0.77 | PPARG (0.34) | FFAR1PPARGPPARAESR1 | |
| SCHEMBL14213711 | 0.77 | FFAR1 (0.33) | FFAR1PPARGPPARAESR1 | |
| SCHEMBL14213658 | 0.77 | FFAR1 (0.32) | FFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322728-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | GLP1R, PPARD, PPARA | FFAR1 44/4885PPARG 4/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.